US Dollar vs MXN

Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.

Regístrate

JAZZ Jazz Pharmaceuticals PLC

127.65

-0.09 (-0.07%)

13 Nov 2024 - Cerrado

Retrasado por 15 minutos

Form 144 - Report of proposed sale of securities

="/Images/box-checked.jpg" alt="Checkbox checked">

144: Remarks and Signature

Remarks

Date of Notice

11/08/2024

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

/s/ Neena M Patil

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

Jazz Pharmaceuticals (NASDAQ:JAZZ)
Gráfica de Acción Histórica
De Oct 2024 a Nov 2024

Haga Click aquí para más Gráficas Jazz Pharmaceuticals.

Jazz Pharmaceuticals (NASDAQ:JAZZ)
Gráfica de Acción Histórica
De Nov 2023 a Nov 2024

Haga Click aquí para más Gráficas Jazz Pharmaceuticals.

Noticias sobre Jazz Pharmaceuticals PLC JAZZ

Form 4 - Statement of changes in beneficial ownership of securities
Miércoles 13 de Noviembre 2024 (7 horas hace) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Viernes 8 de Noviembre 2024 (5 días hace) • Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Jueves 7 de Noviembre 2024 (7 días hace) • Edgar (US Regulatory)

Form 8-K - Current report
Miércoles 6 de Noviembre 2024 (1 semana hace) • Edgar (US Regulatory)

Jazz Pharmaceuticals Announces Third Quarter 2024 Financial Results
Miércoles 6 de Noviembre 2024 (1 semana hace) • PR Newswire (US)

Jazz Pharmaceuticals Presents New Data at Psych Congress 2024 Confirming Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Benefits in Narcolepsy and Idiopathic Hypersomnia
Jueves 31 de Octubre 2024 (2 semanas hace) • PR Newswire (US)

Jazz Pharmaceuticals to Report 2024 Third Quarter Financial Results on November 6, 2024
Miércoles 23 de Octubre 2024 (3 semanas hace) • PR Newswire (US)

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Lunes 21 de Octubre 2024 (3 semanas hace) • Edgar (US Regulatory)

Form 8-K - Current report
Miércoles 16 de Octubre 2024 (4 semanas hace) • Edgar (US Regulatory)

PharmaMar Announces Positive and Statistically Significant Overall Survival and Progression-Free Survival Results for Zepzelca® (lurbinectedin) and Atezolizumab Combination in First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
Martes 15 de Octubre 2024 (4 semanas hace) • PR Newswire (US)

Jazz Pharmaceuticals Announces Statistically Significant Overall Survival and Progression-Free Survival Results for Zepzelca® (lurbinectedin) and Atezolizumab Combination in First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
Martes 15 de Octubre 2024 (4 semanas hace) • PR Newswire (US)

Jazz Pharmaceuticals Presents Updated Phase 2 Data for Zanidatamab Demonstrating Increased mPFS in HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ESMO 2024
Lunes 16 de Septiembre 2024 (2 meses hace) • PR Newswire (US)

Más de Jazz Pharmaceuticals PLC Artículos de Noticias

Energy Services of America

Vontobel Financial Produ...

Vontobel Financial Produ...

Delayed Upgrade Clock

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones